Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

ViiV/GSK NNRTI "761" Development Placed on Hold by FDA

From Positively Aware

February 16, 2011

A promising non-nuke (NNRTI) in development by ViiV, GSK761 (formerly IDX899) was placed on clinical hold by the FDA due to four reports of seizure as part of the Phase 2b trial in treatment experienced patients. Two letters have been sent to study investigators informing them of the events, and including guidance on how to contact patients in order to change their medication from 761 to another suitable alternative and for follow up care.

While this does not mean that development of the drug has been permanently halted, it remains to be seen what the future holds for this drug which, in earlier studies, had shown an improved resistance profile compared to some of the current NNRTIs.




  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by Positively Aware. Visit Positively Aware's website to find out more about the publication.
 
See Also
More on HIV Medications
More on NNRTIs in Development
No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

 

Advertisement